Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05081518 · ClinicalTrials.gov registry record · Phase 1
A Study of Lu AG06466 in Participants With Treatment Resistant Focal Epilepsy
A Phase 1 study, sponsored by H. Lundbeck A/S.
- Terminated
- Registry status
- Phase 1
- Development phase
- 1
- Enrollment target
NCT05081518: Clinical Trial Phase 1 study, sponsored by H. Lundbeck A/S.
NCT05081518 is a Phase 1 study that was terminated before completion, run by H. Lundbeck A/S. The registered enrollment target is 1 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05081518, a Phase 1 study, was terminated before completion, sponsored by H. Lundbeck A/S.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 1 participants
- Enrollment target
Study Summary
The main purpose of this study is to investigate effects of Lu AG06466 on seizure activity after increasing daily doses during 4 weeks in participants with an implanted responsive neurostimulation system.
Primary Outcome
"Long Episodes" are abnormal events detected by the neurostimulator that do not return to baseline ECoG activity within a predefined period of time, typically 30 to 60 seconds. These often correspond to ECoG seizures.
Interventions
- DRUG Placebo
- DRUG Lu AG06466
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2021-09-29 |
| Est. Completion | 2022-04-14 |
| Phase | Phase 1 |
Why NCT05081518 stopped before completion
NCT05081518 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 1 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05081518 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05081518 about?
NCT05081518 is a clinical study titled "A Study of Lu AG06466 in Participants With Treatment Resistant Focal Epilepsy". The main purpose of this study is to investigate effects of Lu AG06466 on seizure activity after increasing daily doses during 4 weeks in participants with an implanted responsive neurostimulation system.
What is the current status of trial NCT05081518?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 1 participants. The study started on 2021-09-29. Estimated completion is 2022-04-14.
What interventions are being tested in trial NCT05081518?
The interventions under investigation include: Placebo (DRUG), Lu AG06466 (DRUG).
Who is sponsoring clinical trial NCT05081518?
This trial is sponsored by H. Lundbeck A/S, which has 72 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05081518's enrollment target sits among peer trials
1 2001st of 2000 the lowest of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI